Rabbit Monoclonal Primary Antibody test as a companion diagnostic to assess HER2+ status in patients with BTC.
Roche (RHHBY) announced that the U.S. Food and Drug Administration has approved an expansion of the PATHWAY anti-HER2/neu (4B5) ...
The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with ...
GlobalData on MSN2d
FDA approves Roche’s PATHWAY HER2 test for biliary tract cancerAccording to Roche, the HER2 (4B5) clone consistently achieves high proficiency assessment scores against other clones. "FDA ...
preclinical and recent clinical data indicate that such resistance might be overcome by inhibiting the HER2 pathway Anti-ER/HER2 concurrent treatment provides significantly better outcomes in HR+ ...
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...
Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...
which indicates that lapatinib exerts its main effects via the HER2 pathway. Around 1.3 million women are diagnosed with breast cancer annually worldwide, which represents 23% of all cancers in women.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback